A case of lichenoid drug eruption associated with relugolix.

The gonadotropin-releasing hormone (GnRH) analogue drug class consists of both GnRH agonists and antagonists, and is primarily used for androgen deprivation therapy in the treatment of prostate cancer. Relugolix is the first and only Food and Drug Administration-approved oral GnRH antagonist for the treatment of adult patients with advanced prostate cancer. Unlike GnRH agonists, relugolix decreases serum testosterone levels without testosterone flares at treatment initiation.1 Eliminating testosterone flares increases the tolerability of this medication by reducing side effects such as ostealgia and urinary retention.